PALMISANO ROBERT J - 17 Jun 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Reporting relationship: Director
Issuer ticker: AEON
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 18:20:49 UTC
Prior SEC filing: 04 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander Wilson, as Attorney-in-Fact, for Robert J. Palmisano

Key filing fact

PALMISANO ROBERT J filed Form 4 for AEON Biopharma, Inc. (AEON) on 22 Jun 2026.

Key facts

This page summarizes PALMISANO ROBERT J's Form 4 filing for AEON Biopharma, Inc. (AEON).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2026, 18:20.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001138646 Primary reporting owner

PALMISANO ROBERT J

Relationship: Director
Address: C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE
Signature: /s/ Alexander Wilson, as Attorney-in-Fact, for Robert J. Palmisano
Signature date: 22 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AEON transaction

Class A Common Stock

Award

Transaction value
Shares: +222,684
Change %: +618%
Price: $0.000000^*
Shares after: 258,705
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.